Drug Shortage Report for PAMIDRONATE DISODIUM FOR INJECTION
Report ID | 181145 |
Drug Identification Number | 02246598 |
Brand name | PAMIDRONATE DISODIUM FOR INJECTION |
Common or Proper name | PAMIDRONATE DISODIUM FOR INJECTION |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | PAMIDRONATE DISODIUM |
Strength(s) | 6MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 10mL |
ATC code | M05BA |
ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2023-04-01 |
Estimated end date | 2023-05-08 |
Actual end date | 2023-05-01 |
Shortage status | Resolved |
Updated date | 2023-05-15 |
Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Pamidronate Disodium for Injection 6 mg/mL SD Vial 10 mL effective April 1, 2023 until May 8, 2023. During this time, our Pamidronate Disodium for Injection 3 mg/mL SD vial 10 mL is available for substitution. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2023-05-15 | French | Compare |
v5 | 2023-05-15 | English | Compare |
v4 | 2023-04-03 | French | Compare |
v3 | 2023-04-03 | English | Compare |
v2 | 2023-01-16 | French | Compare |
v1 | 2023-01-16 | English | Compare |
Showing 1 to 6 of 6